The Association for Clinical Oncology (Association) is governed by a volunteer Board of Directors , which works to ensure that the Association achieves its mission and vision.  Voting Board members are cancer physicians and clinical researchers who volunteer their time. View the Disclosures at the bottom of each individual’s bio. Please direct any questions related to Board members' disclosures to COI@asco.org.

Chair of the Association Board

Monica M. Bertagnolli, MD, FACS, FASCO
View current ASCO disclosure here.

Dr. Bertagnolli is a professor of surgery at Harvard Medical School, and chief of the Division of Surgical Oncology at Brigham and Women’s Hospital and Dana-Farber Cancer Institute. She has worked at the Dana-Farber Cancer Institute and Brigham and Women’s Hospital since 2000. She previously served as an associate surgeon at the Strang Cancer Prevention Center in New York from 1994-2007 and as an attending surgeon at New York Presbyterian Hospital–Cornell from 1994-1999.

Since joining ASCO in 1995, Dr. Bertagnolli has served on the Board of Directors (2007-2011), as well as on numerous committees, including the ASCP/CAP/AMP/ASCO Colorectal Cancer Guidelines Committee (co-chair 2011-present), the Cancer Prevention Committee (2001-2004 and 2007-2010), and the Planning Committee (2008-2011), among others.

In addition to her ASCO involvement, Dr. Bertagnolli currently serves as vice president of Coalition of Cancer Cooperative Groups, chair of Alliance for Clinical Trials in Oncology, president of the Alliance for Clinical Trials in Oncology Foundation, and CEO of Alliance Foundation Trials, LLC. Since 2012 she has served on the National Academy of Medicine’s National Cancer Policy Forum. In 2011, she received the Partners Healthcare Partners in Excellence Award: Personalized Cancer Medicine Partnership Team, and in 2015, she received the CEO Roundtable on Cancer Charles H. Sanders Life Sciences Award.

Dr. Bertagnolli received her undergraduate degree from Princeton University and her medical degree from the University of Utah College of Medicine; she performed her residency at Brigham and Women’s Hospital.

Association Treasurer

Eric J. Small, MD, FASCO​
View current ASCO disclosure here.

Dr. Small is the deputy director and Chief Scientific Officer of the UCSF Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco, and professor in residence in the Department of Medicine and Department of Urology. Dr. Small has worked at the University of California, San Francisco since 1988.

Since joining ASCO in 1992, Dr. Small has served as an associate editor for the Journal of Clinical Oncology (2008-2013), chaired the Molecular Markers Scientific Committee (2008-2009), chaired the Scientific Program Committee (2003-2004), served as the inaugural chair of the Prostate Cancer (Genitourinary Malignancies) Symposium Steering Committee, and served as chair of the Prostate Cancer (Genitourinary Malignancies) Symposium Program Committee (2004-2005). Dr. Small has chaired the grant writing workshop at the ASCO Annual Meeting. Dr. Small also served on the Nominating Committee (2007-2010) and the Conquer Cancer Foundation Grants Selection Committee (2009-2012), among other commitments. Dr. Small was named a Fellow of ASCO (FASCO) in 2015.

In addition to his ASCO involvement, Dr. Small has been a member of the National Cancer Institute Initial Review Group Subcommittee A (Parent Committee for Cancer Centers, 2010-2017), a member of the National Cancer Center Network Treatment Guidelines Panel (1999-2019), and has led a 40-member Stand Up to Cancer Dream Team. Dr. Small served as chair of the CALGB (Alliance) Genitourinary Committee for 14 years, and in 2011, was awarded the Richard L. Schilsky CALGB Award.  He serves as the chair of the External Scientific Advisory Boards for a number of NCI-designated cancer centers, including Fred Hutchinson/University of Washington; Knight Cancer Institute/OHSU; Moores Cancer Center/UCSD; and Sidney Kimmel Cancer Center/Jefferson University. 

Dr. Small received his undergraduate degree from Stanford University and his medical degree from Case Western Reserve University School of Medicine. He performed his internship and residency in internal medicine at Beth Israel Hospital (Boston), and completed his fellowship in Hematology/Oncology at the University of California, San Francisco, where he served as Chief of the Division of Hematology and Oncology for 10 years.

Board Member

Howard A. “Skip” Burris, III, MD, FASCO, FACP
View current ASCO disclosure here.

Dr. Burris serves as president and chief medical officer of Sarah Cannon, as well as the executive director, drug development for the research institute. He is an associate of Tennessee Oncology, PLLC, where he practices medical oncology.

Dr. Burris' clinical research career has focused on the development of new cancer agents with an emphasis on first in human therapies, having led the trials of many novel antibodies, small molecules, and chemotherapies now FDA approved, including ado-trastuzumab emtansine, everolimus, and gemcitabine. In 1997, he established in Nashville the first community based early phase drug development program, which grew into the Sarah Cannon Research Institute. He has authored over 400 publications and 700 abstracts. Sarah Cannon has now dosed over 350 first in human anticancer therapies and enrolls more than 3000 patients per year into clinical trials.

Dr. Burris will serve as the elected president of ASCO in 2019-2020. He also currently serves on the Board of ASCO’s Conquer Cancer Foundation. Additionally in 2014, Dr. Burris was selected by his peers as a Giant of Cancer Care for his achievements in drug development.

Dr. Burris completed his undergraduate education at the United States Military Academy at West Point, his medical degree at the University of South Alabama, and his internal medicine residency and oncology fellowship at Brooke Army Medical Center in San Antonio. While in Texas, he also served as the Director of Clinical Research at The Institute for Drug Development of the Cancer Therapy and Research Center and The University of Texas Health Science Center. He attained the rank of lieutenant colonel in the US Army, and among his decorations, he was awarded a Meritorious Service Medal with oak leaf cluster for his service in Operation Joint Endeavor.  

Board Member

Laurie E. Gaspar, MD, MBA, FASTRO, FACR, FASCO
View current ASCO disclosure here.

Dr. Gaspar grew up in Toronto, Ontario and completed medical school and a residency in radiation oncology at Western University.  Later, after moving to the United States she completed her Masters of Business Administration (MBA) at the University of Michigan.

Dr. Gaspar has been active in many national and international committees, including the ASCO Publications Committee and ASCO’s Annual Program Committees. She is also involved with the American Board of Radiology (ABR), the American Society for Radiation Oncology (ASTRO), NRG (formally RTOG), the International Society for the Study of Lung Cancer (IASLC), and SWOG. She is a Co-Chair of the NCI Thoracic Malignancy Steering Committee. Dr. Gaspar is on the editorial board of Clinical Lung Cancer and Advances in Radiation Oncology. She is the author of more than 200 published articles.

Dr. Gaspar was Professor and Chair of the Department of Radiation Oncology at the University of Colorado for more than 15 years. She is currently Professor Emerita in the Department of Radiation Oncology at the University of Colorado, as well as a staff radiation oncologist at Banner MDA in Northern Colorado.  Dr. Gaspar maintains a long-standing interest in the management of brain tumors and lung cancer.

Board Member

Carolyn Hendricks, MD, FASCO
View current ASCO disclosure here.

Dr. Hendricks specializes in breast cancer and is an active member of a multidisciplinary team focused on breast cancer genetics, screening, and treatment. She provides cutting edge and comprehensive treatment at the local level. Praised for her involvement in clinical trials for breast cancer, she brings knowledge and support to community groups by providing education about breast cancer. Her greatest accomplishments include her ASCO (American Society of Clinical Oncology) volunteer activities both nationally and internationally in the area of quality cancer care. She received the prestigious ASCO Fellowship Award in June 2018.

Board Member

Reshma Jagsi, MD, DPhil, FASTRO​, FASCO
View current ASCO disclosure here.

Dr. Jagsi is Newman Family Professor and deputy chair of the Department of Radiation Oncology and Director of the Center for Bioethics and Social Sciences in Medicine at the University of Michigan, where she is residency program director, treats breast cancer, and conducts health services research.

An ASCO member since 2004, Dr. Jagsi is a past chair of the Ethics Committee (member 2014-2016; chair 2014-2015). She has served on the Scientific Program Committee (2010-2012), and the Journal of Clinical Oncology (JCO) Editorial Board (2013-2015 and 2016-18). Dr. Jagsi participated in ASCO’s Leadership Development Program in 2011-2012 and served as an ASCO representative to the American Medical Association. She also served on the CancerLinQ® Data Governance Oversight Committee and the Bisphosphonates in Breast Cancer and Breast Cancer Consensus Expert Panels.

Dr. Jagsi leverages her research expertise to extend her ASCO service, having published in The New England Journal of Medicine, JAMA, and JCO on issues directly related to her ASCO committee and advocacy experiences. She has an active R01 grant from the National Cancer Institute to study the ethical implementation of CancerLinQ. She has also been active in ASCO’s efforts to promote gender equity (the subject of another R01-funded research program she leads), through its Women’s Networking Center.

Dr. Jagsi received her undergraduate and medical degrees from Harvard, and her doctorate in Social Policy from Oxford as a Marshall Scholar. She completed her residency at the Massachusetts General Hospital/Harvard Radiation Oncology Program (where she was chief resident), as well as a fellowship at the Harvard Center for Ethics.

Board Member

Michael P. Kosty, MD, FACP, FASCO​
View current ASCO disclosure here.

Dr. Kosty is a member of the Scripps Green Cancer Center where he has practiced hematology and medical oncology since 1989. He has served as the director of Scripps Green Cancer Center in La Jolla, California, since 2008, director of Graduate Medical Education at Scripps Clinic/Scripps Green Hospital since 2002, and as director of the Hematology/Oncology Fellow Training Program at Scripps Clinic/Scripps Green Hospital since 1997. Since 1990, he has served at Scripps Green Cancer Center as head of the Thoracic Oncology Service, and as a member of the Genitourinary Oncology Service, Dermatologic Oncology Service, and the Clinical Research Advisory Committee.

Since joining ASCO in 1986, Dr. Kosty has served as the chair of the Continuing Medical Education Subcommittee (2013-2014), the Oncology Training Program Subcommittee (2009-2010) and the Workforce Advisory Group (2015-2016). In addition, he also served as a member of the Test Materials Development Committee and is ASCO co-chair of the European Society of Medical Oncology–ASCO Global Curriculum Workgroup. In recognition of his years of service to ASCO, Dr. Kosty received the distinction of Fellow of ASCO (FASCO) in 2014.

Dr. Kosty served as an investigator for the Southwest Oncology Group from 1999 to 2007 and as an investigator for the Cancer and Leukemia Group B from 1986 to 1999. Dr. Kosty dedicated many years to service in the military, as a general medical officer on the USS Belleau Wood (LHA-3; 1980-1981), as an attending physician and assistant head in the Division of Hematology/Oncology at the Naval Hospital (1986-1989), and as a member of the U.S. Naval Reserve (1989-1999).

Dr. Kosty received his undergraduate and master’s degrees from the University of California, Berkeley. He received his medical degree from George Washington University; he performed his internship, residency, and fellowship at Naval Hospital, San Diego. He was a visiting fellow at the Dana-Farber Cancer Institute at Harvard Medical School and a research fellow at the Scripps Clinic and Research Foundation.

Board Member

Kurt Oettel, MD
View current ASCO disclosure here.

Dr. Oettel is an oncologist in La Crosse, Wisconsin and is affiliated with multiple hospitals in the area, including Black River Memorial Hospital and Gundersen Lutheran Medical Center. He received his medical degree from University of Wisconsin School of Medicine and Public Health and has been in practice for more than 20 years.

 

 

Board Member

Lori J. Pierce, MD, FASTRO, FASCO
View current ASCO disclosure here.

Dr. Pierce is a radiation oncologist, professor, and Vice Provost for Academic and Faculty Affairs at the University of Michigan. She is also director of the Michigan Radiation Oncology Quality Consortium. A national leader in breast cancer research, Dr. Pierce was previously a Senior Investigator at the National Cancer Institute, National Institutes of Health and in 1992, joined the faculty at the University of Michigan where she has focused her career primarily on the treatment of breast cancer.

An active ASCO member since 1992, Dr. Pierce is a past member of multiple ASCO committees including the Government Relations Committee, Annual Meeting Scientific Program Committee and the Conquer Cancer Foundation Nominating Committee, and she served as a mentor for the Leadership Development Program from 2015 to 2018. She previously served on the ASCO Board of Directors from 2010 – 2014 and was named a Fellow of ASCO (FASCO) in 2015. 

With over 180 manuscripts and book chapters published, Dr. Pierce has received numerous teaching and leadership awards including the American Association of Women Radiologoists’ Marie Curie Award and the Hologic, Inc Endowed Women Who Conquer Cancer Mentorship Award. In 2018, she was elected into the National Academy of Medicine. Most recently, Dr. Pierce was selected as the 2019 Woman of the Year by the United Way of Washtenaw County (UWWC) of Michigan.

Dr. Pierce completed her undergraduate degree in biomedical engineering at the University of Pennsylvania and her medical degree at Duke University. She completed her internship at the Thomas Jefferson University Hospital and her residency and chief residency in Radiation Oncology at the University of Pennsylvania.

Board Member

Everett E. Vokes, MD, FASCO
View current ASCO disclosure here.

Dr. Vokes is the John E. Ultmann Professor, chair of the Department of Medicine, and physician-in-chief at the University of Chicago Medicine and Biological Sciences. He is the former leader of the Respiratory Committee of the Alliance (formerly Cancer and Leukemia Group B) and serves on the editorial boards of several journals. He is a past chair of the Annual Meeting Education Committee, Annual Meeting Scientific Program Committee, a member of the Conquer Cancer Development and Fundraising Committee, and a member of the Cancer.Net Editorial Board. He served as an elected member of the ASCO Nominating Committee, and on the Board of Directors from 2009-2012.

Non-Voting Board Member- Chief Executive Officer

Clifford A. Hudis, MD, FACP, FASCO
View current ASCO disclosure here.

Dr. Hudis is the Chief Executive Officer of  the Association for Clinical Oncology. He also serves as the Chief Executive Officer of the American Society of Clinical Oncology and Conquer Cancer, the ASCO Foundation, and as the Chairman of the Board of Governors of ASCO’s CancerLinQ. Dr. Hudis previously served in a variety of roles at ASCO, including as President during the Society’s 50th anniversary year (2013-14). Before transitioning full-time to ASCO, he was the Chief of the Breast Medicine Service at Memorial Sloan Kettering Cancer Center (MSKCC) in New York City, where he was also Professor of Medicine at the Weill Medical College of Cornell University. In this role, he developed more effective treatments for all stages of breast cancer, while also exploring novel prevention opportunities. As CEO, Dr. Hudis’ focus is on education, research and promotion of the highest quality of care by ASCO’s nearly 45,000 members. Key initiatives include the acceleration of CancerLinQ, ASCO’s focused effort to increase insights and learning from the rapidly accumulating electronic records of routine care provided by clinicians.